The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
NK cell-based immunotherapy for cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Kiessling, R., Klein, E., & Wigzell, H. (1975) · European Journal of Immunology · doi:10.1002/eji.1830050208 · Cited by 1,824
Herberman, R. B., Nunn, M. E., & Lavrin, D. H. (1975) · International Journal of Cancer · doi:10.1002/ijc.2910160204 · Cited by 1,355
Liver immunology and its role in inflammation and homeostasis
Robinson, M. W., Harmon, C., & O’Farrelly, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.3 · Cited by 1,151
Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 887
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Natural killer cells and dendritic cells: rendezvous in abused tissues
Moretta, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri956 · Cited by 704
Phillips, J. H., & Lanier, L. L. (1986) · The Journal of experimental medicine · doi:10.1084/jem.164.3.814 · Cited by 684
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Self-citationNKG2D Receptor and Its Ligands in Host Defense
Lanier, L. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0098 · Cited by 599
Natural killer cell memory in infection, inflammation and cancer
Cerwenka, A., & Lanier, L. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.9 · Cited by 576
Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., Su, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P., et al. (2012) · Nature · doi:10.1038/nature10975 · Cited by 552
Sojka, D. K., Plougastel-Douglas, B., Yang, L., Pak-Wittel, M. A., Artyomov, M. N., Ivanova, Y., Zhong, C., Chase, J. M., Rothman, P. B., Yu, J., et al. (2014) · eLife · doi:10.7554/elife.01659 · Cited by 547
Self-citationLiver-resident NK cells confer adaptive immunity in skin-contact inflammation
Peng, H., Jiang, X., Chen, Y., Sojka, D. K., Wei, H., Gao, X., Sun, R., Yokoyama, W. M., & Tian, Z. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66381 · Cited by 545
Self-citationCostello, R. T., Sivori, S., Marcenaro, E., Lafage-Pochitaloff, M., Mozziconacci, M.-J., Reviron, D., Gastaut, J.-A., Pende, D., Olive, D., & Moretta, A. (2002) · Blood · doi:10.1182/blood.v99.10.3661 · Cited by 500
Balancing natural killer cell activation through paired receptors
Martinet, L., & Smyth, M. J. (2015) · Nature Reviews Immunology · doi:10.1038/nri3799 · Cited by 485
Parkhurst, M. R., Riley, J. P., Dudley, M. E., & Rosenberg, S. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1347 · Cited by 475
Van Tendeloo, V. F. I., Ponsaerts, P., Lardon, F., Nijs, G., Lenjou, M., Van Broeckhoven, C., Van Bockstaele, D. R., & Berneman, Z. N. (2001) · Blood · doi:10.1182/blood.v98.1.49 · Cited by 468
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., & Marcenaro, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.025 · Cited by 465
Chu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R., Carson, L. F., Argenta, P. A., Jonson, A. L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2010.515582 · Cited by 436
Bachanova, V., Cooley, S., Defor, T. E., Verneris, M. R., Zhang, B., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532531 · Cited by 435
TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy
Dougall, W. C., Kurtulus, S., Smyth, M. J., & Anderson, A. C. (2017) · Immunological Reviews · doi:10.1111/imr.12518 · Cited by 435
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
da Silva, I. P., Gallois, A., Jimenez-Baranda, S., Khan, S., Anderson, A. C., Kuchroo, V. K., Osman, I., & Bhardwaj, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0171 · Cited by 424
Knorr, D. A., Ni, Z., Hermanson, D., Hexum, M. K., Bendzick, L., Cooper, L. J. N., Lee, D. A., & Kaufman, D. S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0084 · Cited by 415
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
CIS is a potent checkpoint in NK cell–mediated tumor immunity
Delconte, R. B., Kolesnik, T. B., Dagley, L. F., Rautela, J., Shi, W., Putz, E. M., Stannard, K., Zhang, J.-G., Teh, C., Firth, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3470 · Cited by 384
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.21335 · Cited by 378
Gleason, M. K., Lenvik, T. R., McCullar, V., Felices, M., O'Brien, M. S., Cooley, S. A., Verneris, M. R., Cichocki, F., Holman, C. J., Panoskaltsis-Mortari, A., et al. (2012) · Blood · doi:10.1182/blood-2011-06-360321 · Cited by 373
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
Chang, Y.-H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Suck, G., Odendahl, M., Nowakowska, P., Seidl, C., Wels, W. S., Klingemann, H. G., & Tonn, T. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1761-x · Cited by 328
Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., Balsamo, M., Conte, R., Benelli, R., Minghelli, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2544 · Cited by 324
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi-Ferchiou, A., Lambert, M., Dogniaux, S., Vély, F., Vivier, E., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312
Yang, Z.-Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., Witzig, T. E., & Ansell, S. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59806 · Cited by 309
Horst, A. K., Neumann, K., Diehl, L., & Tiegs, G. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.112 · Cited by 295
FOXP3+ regulatory T cells and their functional regulation
Li, Z., Li, D., Tsun, A., & Li, B. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.10 · Cited by 290
Miller, J. S., Cooley, S., Parham, P., Farag, S. S., Verneris, M. R., McQueen, K. L., Guethlein, L. A., Trachtenberg, E. A., Haagenson, M., Horowitz, M. M., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065383 · Cited by 288
Gollob, J., Mier, J. W., Veenstra, K. G., McDermott, D. F., Clancy, D., Clancy, M., & Atkins, M. B. (2000) · PubMed · Cited by 285
Iliopoulou, E. G., Kountourakis, P., Karamouzis, M. V., Doufexis, D., Ardavanis, A., Baxevanis, C. N., Rigatos, G., Papamichail, M., & Perez, S. A. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0904-3 · Cited by 277
Sakamoto, N., Ishikawa, T., Kokura, S., Okayama, T., Oka, K., Ideno, M., Sakai, F., Kato, A., Tanabe, M., Enoki, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0632-8 · Cited by 270
Are natural killer cells superior CAR drivers?
Klingemann, H. (2014) · OncoImmunology · doi:10.4161/onci.28147 · Cited by 270
Jiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F., Zeng, T., Huang, H., Zhang, X., Sun, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.001 · Cited by 267
Gleason, M. K., Ross, J. A., Warlick, E. D., Lund, T. C., Verneris, M. R., Wiernik, A., Spellman, S., Haagenson, M. D., Lenvik, A. J., Litzow, M. R., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533398 · Cited by 266
Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
Hermanson, D. L., Bendzick, L., Pribyl, L., McCullar, V., Vogel, R. I., Miller, J. S., Geller, M. A., & Kaufman, D. S. (2016) · Stem Cells · doi:10.1002/stem.2230 · Cited by 242
Chen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., Chen, L., Wang, Y., Wang, H., Yi, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8526 · Cited by 242
Spanholtz, J., Preijers, F., Tordoir, M., Trilsbeek, C., Paardekooper, J., de Witte, T., Schaap, N., & Dolstra, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020740 · Cited by 238
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Childs, R. W., & Carlsten, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4506 · Cited by 236
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Ochoa, M. C., Minute, L., Rodriguez, I., Garasa, S., Perez‐Ruiz, E., Inogés, S., Melero, I., & Berraondo, P. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2017.6 · Cited by 230
Floros, T., & Tarhini, A. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.015 · Cited by 229
Moretta, L., Locatelli, F., Pende, D., Marcenaro, E., Mingari, M. C., & Moretta, A. (2011) · Blood · doi:10.1182/blood-2010-08-264085 · Cited by 229
Wiernik, A., Foley, B., Zhang, B., Verneris, M. R., Warlick, E., Gleason, M. K., Ross, J. A., Luo, X., Weisdorf, D. J., Walcheck, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0505 · Cited by 226
Romanski, A., Uherek, C., Bug, G., Seifried, E., Klingemann, H., Wels, W. S., Ottmann, O. G., & Tonn, T. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12810 · Cited by 220
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
Lapteva, N., Durett, A. G., Sun, J., Rollins, L. A., Huye, L. L., Fang, J., Dandekar, V., Mei, Z., Jackson, K., Vera, J., et al. (2012) · Cytotherapy · doi:10.3109/14653249.2012.700767 · Cited by 216
Human Circulating and Tissue-Resident CD56bright Natural Killer Cell Populations
Melsen, J. E., Lugthart, G., Lankester, A. C., & Schilham, M. W. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00262 · Cited by 214
Müller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H.-G., Tonn, T., & Wels, W. S. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0383-3 · Cited by 212
Dolstra, H., Roeven, M. W. H., Spanholtz, J., Hangalapura, B. N., Tordoir, M., Maas, F., Leenders, M., Bohme, F., Kok, N., Trilsbeek, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2981 · Cited by 210
Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M., & Rossig, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2810 · Cited by 206
Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa, E., Tsuboi, K., Saijo, K., Harada, H., Takano, S., Nose, T., & Ohno, T. (2004) · PubMed · Cited by 201
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma
Sun, C., Sun, H., Zhang, C., & Tian, Z. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.91 · Cited by 200
Self-citationNatural Killer Cell Responses to Viral Infection
Brandstadter, J. D., & Yang, Y. (2011) · Journal of Innate Immunity · doi:10.1159/000324176 · Cited by 200
Shah, N., Martin-Antonio, B., Yang, H., Ku, S., Lee, D. A., Cooper, L. J. N., Decker, W. K., Li, S., Robinson, S. N., Sekine, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076781 · Cited by 199
Alici, E., Sutlu, T., Björkstrand, B., Gilljam, M., Stellan, B., Nahi, H., Quezada, H. C., Gahrton, G., Ljunggren, H.-G., & Dilber, M. S. (2008) · Blood · doi:10.1182/blood-2007-09-110312 · Cited by 197
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R., Blankenstein, T., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 197
Chester, C., Fritsch, K., & Kohrt, H. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00601 · Cited by 195
Boissel, L., Betancur, M., Lu, W., Krause, D., Van Etten, R., Wels, W., & Klingemann, H. (2013) · OncoImmunology · doi:10.4161/onci.26527 · Cited by 194
Sanmamed, M. F., Pastor, F., Rodriguez, A., Perez-Gracia, J. L., Rodriguez-Ruiz, M. E., Jure-Kunkel, M., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.014 · Cited by 190
Esser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
Sahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Szmania, S., Lapteva, N., Garg, T., Greenway, A., Lingo, J., Nair, B., Stone, K., Woods, E., Khan, J., Stivers, J., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000059 · Cited by 184
Jochems, C., Hodge, J. W., Fantini, M., Fujii, R., Morillon, Y. M., Greiner, J. W., Padget, M. R., Tritsch, S. R., Yok Tsang, K., Campbell, K. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13411 · Cited by 182
Liver natural killer cells: subsets and roles in liver immunity
Peng, H., Wisse, E., & Tian, Z. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.96 · Cited by 181
Self-citationBenson, D. M., Cohen, A. D., Jagannath, S., Munshi, N. C., Spitzer, G., Hofmeister, C. C., Efebera, Y. A., Andre, P., Zerbib, R., & Caligiuri, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0304 · Cited by 180
Allogeneic natural killer cells for refractory lymphoma
Bachanova, V., Burns, L. J., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lindgren, B. R., Cooley, S., Weisdorf, D., & Miller, J. S. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0896-z · Cited by 177
Shimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T., Eldridge, P., Leung, W., & Campana, D. (2012) · Cytotherapy · doi:10.3109/14653249.2012.671519 · Cited by 177
Development and maturation of natural killer cells
Geiger, T. L., & Sun, J. C.-Y. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.01.007 · Cited by 175
Chu, Y., Hochberg, J., Yahr, A., Ayello, J., van de Ven, C., Barth, M., Czuczman, M., & Cairo, M. S. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0114 · Cited by 174
Clinical utility of natural killer cells in cancer therapy and transplantation
Knorr, D. A., Bachanova, V., Verneris, M. R., & Miller, J. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.002 · Cited by 170
Boissel, L., Betancur, M., Wels, W. S., Tuncer, H., & Klingemann, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.024 · Cited by 166
Li, Y.-H., Zhou, W.-H., Tao, Y., Wang, S.-C., Jiang, Y.-L., Zhang, D., Piao, H.-L., Fu, Q., Li, D.-J., & Du, M.-R. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.126 · Cited by 165
Agaugué, S., Marcenaro, E., Ferranti, B., Moretta, L., & Moretta, A. (2008) · Blood · doi:10.1182/blood-2008-02-135871 · Cited by 165
Sutlu, T., Nyström, S., Gilljam, M., Stellan, B., Applequist, S. E., & Alici, E. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.080 · Cited by 162
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Fallon, J., Tighe, R., Kradjian, G., Guzman, W., Bernhardt, A., Neuteboom, B., Lan, Y., Sabzevari, H., Schlom, J., & Greiner, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1853 · Cited by 160
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Ruggeri, L., Urbani, E., Andre, P., Mancusi, A., Tosti, A., Topini, F., Blery, M., Animobono, L., Romagne, F., Wagtmann, N., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.135301 · Cited by 160
Rosario, M., Liu, B., Kong, L., Collins, L. I., Schneider, S. E., Chen, X., Han, K., Jeng, E. K., Rhode, P. R., Leong, J. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1419 · Cited by 158
Yang, Y., Lim, O., Kim, T. M., Ahn, Y., Choi, H., Chung, H., Min, B., Her, J. H., Cho, S., Keam, B., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0118 · Cited by 155
Shaffer, B. C., Luduec, J.-B. L., Forlenza, C. J., Jakubowski, A. A., Perales, M., Young, J. W., & Hsu, K. C. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.12.028 · Cited by 151
Human natural killer cell development in secondary lymphoid tissues
Freud, A. G., Yu, J., & Caligiuri, M. A. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.008 · Cited by 150
Gollob, J., Veenstra, K. G., Parker, R. A., Mier, J. W., McDermott, D. F., Clancy, D., Tutin, L., Koon, H. B., & Atkins, M. B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.119 · Cited by 148
Boissel, L., Betancur, M., Lu, W., Wels, W. S., Marino, T., Etten, R. A. V., & Klingemann, H. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.634048 · Cited by 146
Li, L., Liu, L. N., Feller, S., Allen, C., Shivakumar, R., Fratantoni, J. C., Wolfraim, L. A., Fujisaki, H., Campana, D., Chopas, N., et al. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.61 · Cited by 144
Sütlü, T., Stellan, B., Gilljam, M., Quezada, H. C., Nahi, H., Gahrton, G., & Alici, E. (2010) · Cytotherapy · doi:10.3109/14653249.2010.504770 · Cited by 137
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Korde, N., Carlsten, M., Lee, M.-J., Minter, A., Tan, E. M., Kwok, M., Manasanch, E. E., Bhutani, M., Tageja, N., Roschewski, M. J., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.103085 · Cited by 137
Somanchi, S. S., Somanchi, A., Cooper, L. J. N., & Lee, D. A. (2012) · Blood · doi:10.1182/blood-2011-11-389924 · Cited by 135
Activated T cells and cytokine-induced CD3 + CD56 + killer cells
Schmidt‐Wolf, G., Negrin, R. S., & Schmidt‐Wolf, I. G. H. (1997) · Annals of Hematology · doi:10.1007/s002770050257 · Cited by 134
Prospects for TIM3-Targeted Antitumor Immunotherapy
Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1487 · Cited by 131
Gao, B. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.09 · Cited by 131
Features of Memory-Like and PD-1+ Human NK Cell Subsets
Chiesa, M. D., Pesce, S., Muccio, L., Carlomagno, S., Sivori, S., Moretta, A., & Marcenaro, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00351 · Cited by 129
Mattiola, I., Pesant, M., Tentorio, P., Molgora, M., Marcenaro, E., Lugli, E., Locati, M., & Mavilio, D. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500325 · Cited by 126
Nagashima, S., Mailliard, R. B., Kashii, Y., Reichert, T. E., Herberman, R. B., Robbins, P. D., & Whiteside, T. L. (1998) · Blood · doi:10.1182/blood.v91.10.3850 · Cited by 121
Propagation of large numbers of T cells with natural killer cell markers
Schmidt‐Wolf, I. G. H., Lefterova, P., Johnston, V., Huhn, D., Blume, K. G., & Negrin, R. S. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb08297.x · Cited by 121
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0188-3 · Cited by 117
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy
Garg, T. K., Szmania, S. M., Khan, J. A., Hoering, A., Malbrough, P., Moreno-Bost, A. M., Greenway, A. D., Lingo, J. D., Li, X., Yaccoby, S., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.056747 · Cited by 116
Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer
Davis, Z., Felices, M., Verneris, M. R., & Miller, J. S. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000156 · Cited by 114
Adaptive immunity in the liver
Shuai, Z., Leung, M. W., He, X.-S., Zhang, W., Yang, G., Leung, P. S. C., & Gershwin, M. E. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.4 · Cited by 113
Schmohl, J., Gleason, M., Dougherty, P., Miller, J. S., & Vallera, D. A. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0391-8 · Cited by 112
Harnessing NK Cell Memory for Cancer Immunotherapy
Fehniger, T. A., & Cooper, M. A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.005 · Cited by 111
Bottino, C., Dondero, A., Bellora, F., Moretta, L., Locatelli, F., Pistoia, V., Moretta, A., & Castriconi, R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00056 · Cited by 108
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
Carotta, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00152 · Cited by 107
Fine, J. H., Chen, P., Mesci, A., Allan, D., Gasser, S., Raulet, D. H., & Carlyle, J. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1316 · Cited by 105
Replicative potential of human natural killer cells
Fujisaki, H., Kakuda, H., Imai, C., Mullighan, C. G., & Campana, D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07667.x · Cited by 103
Zhang, S., Xing, K., Zeng, S., Wu, M. C., Lou, J., Wu, L., Huang, P., Huang, L., Wang, F., & Pan, S. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.57 · Cited by 101
Granzin, M., Stojanovic, A., Miller, M., Childs, R. W., Huppert, V., & Cerwenka, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1219007 · Cited by 98
Therapeutic applications: natural killer cells in the clinic
Miller, J. S. (2013) · Hematology · doi:10.1182/asheducation-2013.1.247 · Cited by 96
Zanoni, I., Spreafico, R., Bodio, C., Gioia, M. D., Cigni, C., Broggi, A., Gorletta, T., Caccia, M., Chirico, G. G., Sironi, L., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.021 · Cited by 96
Giuliani, M., Janji, B., & Berchem, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15234 · Cited by 95
Cany, J., van der Waart, A. B., Tordoir, M., Franssen, G. M., Hangalapura, B. N., de Vries, I. J. M., Boerman, O. C., Schaap, N. P., van der Voort, R., Spanholtz, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064384 · Cited by 94
Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-680546 · Cited by 93
Cord Blood as a Source of Natural Killer Cells
Mehta, R. S., Shpall, E. J., & Rezvani, K. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2015.00093 · Cited by 91
Leivas, A., Pérez‐Martínez, A., Blanchard, M. J., Martín‐Clavero, E., Fernández, L., Lahuerta, J. J., & Martínez‐López, J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1250051 · Cited by 91
The breast tumor microenvironment alters the phenotype and function of natural killer cells
Krneta, T., Gillgrass, A. E., Chew, M. V., & Ashkar, A. A. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.42 · Cited by 90
Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
James, A. M., Cohen, A. D., & Campbell, K. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00481 · Cited by 90
Expanded and armed natural killer cells for cancer treatment
Shimasaki, N., Coustan‐Smith, E., Kamiya, T., & Campana, D. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.06.013 · Cited by 90
Béziat, V., Hilton, H. G., Norman, P. J., & Traherne, J. A. (2016) · Immunology · doi:10.1111/imm.12684 · Cited by 90
Natural killer cells: a review of manufacturing and clinical utility
Koepsell, S. A., Miller, J. S., & McKenna, D. H. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03724.x · Cited by 88
Zhu, Y., Huang, B. Y., & Shi, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9980 · Cited by 83
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
Pittari, G., Filippini, P., Gentilcore, G., Grivel, J., & Rutella, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00230 · Cited by 81
Pérez‐Martínez, A., Fernández, L., Valentín, J., Martínez-Romera, I., Corral, M. D., Ramírez, M. R., Abad, L., Santamaría, S., González‐Vicent, M., Sirvent, S. I., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.07.011 · Cited by 80
Srivastava, S., Pelloso, D., Feng, H., Voiles, L., Lewis, D., Hašková, Z., Whitacre, M., Trulli, S. H., Chen, Y.-J., Toso, J. F., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1403-0 · Cited by 80
Oyer, J. L., Igarashi, R. Y., Kulikowski, A. R., Colosimo, D. A., Solh, M., Zakari, A., Khaled, Y. A., Altomare, D. A., & Copik, A. J. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.037 · Cited by 73
Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
Tassev, D. V., Cheng, M., & Cheung, N. K. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.66 · Cited by 72
Tissue resident regulatory T cells: novel therapeutic targets for human disease
Zhou, X., Tang, J., Cao, H., Fan, H., & Li, B. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.23 · Cited by 71
Positive and Negative Regulation by NK Cells in Cancer
Sungur, C. M., & Murphy, W. J. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014010805 · Cited by 71
Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody
Zhang, G., Liu, R., Zhu, X., Wang, L., Ma, J., Han, H., Wang, X., Zhang, G., He, W. Z., Wang, W., et al. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.45 · Cited by 70
Lundqvist, A., Berg, M., Smith, A. L., & Childs, R. W. (2011) · Journal of Cancer · doi:10.7150/jca.2.383 · Cited by 70
Nielsen, C. M., Wolf, A., Goodier, M. R., & Riley, E. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00101 · Cited by 70
Xing, D., Ramsay, A. G., Gribben, J. G., Decker, W. K., Burks, J. K., Munsell, M., Li, S., Robinson, S. N., Yang, H. Y., Steiner, D., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181e475e9 · Cited by 69
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
Ghasemi, R., Lazear, E., Wang, X., Arefanian, S., Zheleznyak, A., Carreno, B. M., Higashikubo, R., Gelman, A. E., Kreisel, D., Fremont, D. H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12878 · Cited by 69
PD-1 says goodbye, TIM-3 says hello
Romero, D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.40 · Cited by 68
Rodella, L. F., Zamai, L., Rezzani, R., Artico, M., Peri, G., Falconi, M., Facchini, A., Pelusi, G., & Vitale, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03055.x · Cited by 66
Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
Davies, J. O. J., Stringaris, K., Barrett, A. J., & Rezvani, K. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.009 · Cited by 65
Positive and negative regulation of Natural Killer cells: Therapeutic implications
Hallett, W. H. D., & Murphy, W. J. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.003 · Cited by 63
Spreu, J., Kuttruff, S., Stejfova, V., Dennehy, K. M., Schittek, B., & Steinle, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913108107 · Cited by 63
Human NK cells and NK receptors
Bellora, F., Castriconi, R., Dondero, A., Carrega, P., Mantovani, A., Ferlazzo, G., Moretta, A., & Bottino, C. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.12.009 · Cited by 62
T-Cell Ig and ITIM Domain Regulates Natural Killer Cell Activation in Murine Acute Viral Hepatitis
Bi, J., Zhang, Q., Liang, D., Xiong, L., Wei, H., Sun, R., & Tian, Z. (2013) · Hepatology · doi:10.1002/hep.26968 · Cited by 59
Self-citationRen, J., Nie, Y., Lv, M., Shen, S., Tang, R., Xu, Y., Hou, Y., Zhao, S., & Wang, T. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.101 · Cited by 58
Tissue-Resident Natural Killer Cells
Yokoyama, W. M., Sojka, D. K., Peng, H. C., & Tian, Z. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.020354 · Cited by 58
Self-citationBispecific antibodies in cancer immunotherapy
Chen, S., Li, J., Li, Q., & Wang, Z. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1187802 · Cited by 57
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
Koerner, S., Andre, M. C., Leibold, J., Kousis, P. C., Kübler, A., Pal, M., Haen, S. P., Bühring, H.-J., Grosse-Hovest, L., Jung, G., et al. (2016) · Leukemia · doi:10.1038/leu.2016.194 · Cited by 56
Morvan, M. G., David, G., Sébille, V., Perrin, A., Gagne, K., Willem, C., Kerdudou, N., Denis, L., Clémenceau, B., Folléa, G., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200838407 · Cited by 53
Chen, Y., Chen, B., Yang, T., Xiao, W., Qian, L., Ding, Y., Ming-chun, J., Ge, X., & Gong, W. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.81 · Cited by 52
Self-citationJiang, W., Zhang, J., & Tian, Z. (2008) · Cytotherapy · doi:10.1080/14653240801965156 · Cited by 49
Self-citationActivating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells
Zhang, H., Cui, Y., Voong, N., Sabatino, M., Stroncek, D. F., Morisot, S., Civin, C. I., Wayne, A. S., Levine, B. L., & Mackall, C. L. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31820d2a21 · Cited by 49
Masuyama, J., Murakami, T., Iwamoto, S., & Fujita, S. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.09.011 · Cited by 49
PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
Rekik, R., Hmida, N. B., Hmid, A. B., Zamali, I., Kammoun, N., & Ahmed, M. B. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.104 · Cited by 47
Deng, X., Terunuma, H., Nieda, M., Xiao, W., & Nicol, A. J. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.09.014 · Cited by 47
Self-citationManufacturing Natural Killer Cells as Medicinal Products
Chabannon, C., Mfarrej, B. G., Guia, S., Ugolini, S., Devillier, R., Blaise, D., Vivier, É., & Calmels, B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00504 · Cited by 47
Klingemann, H., Grodman, C., Cutler, E., Duque, M., Kadidlo, D. M., Klein, A., Sprague, K. A., Miller, K. B., Comenzo, R., Kewalramani, T., et al. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03764.x · Cited by 46
Carrega, P., Pezzino, G., Queirolo, P., Bonaccorsi, I., Falco, M., Vita, G., Pende, D., Misefari, A., Moretta, A., Mingari, M. C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008132 · Cited by 46
Natural Killer Cells for Therapy of Leukemia
Suck, G., Linn, Y. C., & Tonn, T. (2016) · Transfusion Medicine and Hemotherapy · doi:10.1159/000445325 · Cited by 45
Anti-GITR therapy promotes immunity against malignant glioma in a murine model
Miska, J. M., Rashidi, A., Chang, A. L., Muroski, M. E., Han, Y., Zhang, L., & Lesniak, M. S. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1912-8 · Cited by 43
Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes
Pillet, A.-H., Thèze, J., & Rose, T. (2011) · Human Immunology · doi:10.1016/j.humimm.2011.07.311 · Cited by 42
Thaysen‐Andersen, M., Chertova, E. N., Bergamaschi, C., Moh, E. S. X., Chertov, O., Roser, J. D., Sowder, R., Bear, J., Lifson, J. D., Packer, N. H., et al. (2015) · Glycoconjugate Journal · doi:10.1007/s10719-015-9627-1 · Cited by 41
Lehmann, D., Spanholtz, J., Sturtzel, C., Tordoir, M., Schlechta, B., Groenewegen, D., & Hofer, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087131 · Cited by 40
Kellner, C., Guenther, A., Humpe, A., Repp, R., Klausz, K., Derer, S., Valerius, T., Ritgen, M., Brüggemann, M., van de Winkel, J. G. J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1058459 · Cited by 38
Veluchamy, J. P., Heeren, A. M., Spanholtz, J., van Eendenburg, J. D. H., Heideman, D. A. M., Kenter, G. G., Verheul, H. M. W., van der Vliet, H. J., Jordanova, E. S., & de Gruijl, T. D. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1919-1 · Cited by 38
Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21
Li, X., He, C., Liu, C., Ma, J., Ma, P., Cui, H., Tao, H., & Gao, B. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3005 · Cited by 36
Organ-specific phenotypic and functional features of NK cells in humans
Sharma, R., & Das, A. (2013) · Immunologic Research · doi:10.1007/s12026-013-8477-9 · Cited by 36
Critical roles of co‐activation receptor DNAX accessory molecule‐1 in natural killer cell immunity
Peng, X., Sang, H., & Zhu, M. (2015) · Immunology · doi:10.1111/imm.12516 · Cited by 35
Steinbacher, J., Baltz‐Ghahremanpour, K., Schmiedel, B. J., Steinle, A., Jung, G., Kübler, A., Andre, M. C., Große‐Hovest, L., & Salih, H. R. (2014) · International Journal of Cancer · doi:10.1002/ijc.29083 · Cited by 35
Melanoma Immunotherapy: Historical Precedents, Recent Successes and Future Prospects
Raaijmakers, M. I. G., Rozati, S., Goldinger, S. M., Widmer, D. S., Dummer, R., & Levesque, M. P. (2013) · Immunotherapy · doi:10.2217/imt.12.162 · Cited by 34
Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects
Gokhale, M., Vainstein, V., Tom, J., Thomas, S., Lawrence, C. E., Gluzman‐Poltorak, Z., Siebers, N., & Basile, L. A. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-11 · Cited by 30
Large Volume Flow Electroporation of mRNA: Clinical Scale Process
Li, L., Allen, C., Shivakumar, R., & Peshwa, M. V. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_9 · Cited by 26
Arming NK cells with enhanced antitumor activity: CARs and beyond
Oberoi, P., & Wels, W. S. (2013) · OncoImmunology · doi:10.4161/onci.25220 · Cited by 25
Tissue-resident natural killer cells in the livers
Peng, H. C., & Tian, Z. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-0334-2 · Cited by 25
Self-citationAyello, J. S., Hochberg, J. C., Flower, A. M., Chu, Y., Baxi, L., Quish, W., van de Ven, C., & Cairo, M. S. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.10.003 · Cited by 23
Pawlick, R. L., Gala-López, B., Pepper, A. R., McCall, M., Ziff, O. J., & Shapiro, A. M. J. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12838 · Cited by 16
Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?
Felices, M., & Miller, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1582 · Cited by 14
Kohrt, H. E. K., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P. J., Czerwinski, D. K., Sunwoo, J. B., Tedder, T. J., Chen, L., & Levy, R. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-lb-138 · Cited by 1
Cited by
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
COVID-19: immunopathogenesis and Immunotherapeutics
Yang, L., Liu, S., Liu, J., Zhang, Z., Wan, X., Huang, B., Chen, Y., & Zhang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00243-2 · Cited by 912
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Metadata
- Authors
- Fang, F., Xiao, W., & Tian, Z.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 31
- Pages
- 37-54
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W2753630019
- Cited by
- 306
- References
- 191
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.